Published in Clin Pharmacol Ther on August 01, 1975
Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy. Support Care Cancer (2014) 0.83
Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol (2014) 0.81
Single-dose dexamethasone for mild-to-moderate asthma exacerbations: effective, easy, and acceptable. Can Fam Physician (2011) 0.81
Glucocorticoid enhances hypoxia- and/or transforming growth factor-β-induced plasminogen activator inhibitor-1 production in human proximal renal tubular cells. Clin Exp Nephrol (2010) 0.80
Cortisol and dexamethasone elimination during treatment with cimetidine. Br J Clin Pharmacol (1984) 0.78
Injectable dexamethasone sodium phosphate administered orally? A pharmacokinetic analysis of a common emergency department practice. J Pediatr Pharmacol Ther (2015) 0.75
Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Support Care Cancer (2016) 0.75
Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial. Osteoporos Int (2017) 0.75
The composite genome of the legume symbiont Sinorhizobium meliloti. Science (2001) 9.11
A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinet Biopharm (1978) 3.47
PKS1, a substrate phosphorylated by phytochrome that modulates light signaling in Arabidopsis. Science (1999) 3.42
Nucleotide sequence and predicted functions of the entire Sinorhizobium meliloti pSymA megaplasmid. Proc Natl Acad Sci U S A (2001) 2.59
A phytochrome from the fern Adiantum with features of the putative photoreceptor NPH1. Proc Natl Acad Sci U S A (1998) 1.93
Selective inhibitors of biosynthesis of aminergic neurotransmitters. Nature (1978) 1.88
Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother (1983) 1.86
Aux/IAA proteins are phosphorylated by phytochrome in vitro. Plant Physiol (2000) 1.85
Pharmacokinetics and comparative pharmacology of cefoxitin and cephalosporins. Rev Infect Dis (1989) 1.60
Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis (1999) 1.54
An assay for transaminase B enzyme activity in Escherichia coli K-12. Anal Biochem (1973) 1.49
Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother (1978) 1.46
Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol (1975) 1.46
The metabolism of indomethacin in man. J Pharmacol Exp Ther (1972) 1.44
Ordering of mutant sites in the isoleucine-valine genes of Escherichia coli by use of merogenotes derived from F 14 : a new procedure for fine-structure mapping. J Bacteriol (1972) 1.42
Herpes simplex virus infection blocks events in the G1 phase of the cell cycle. Virology (2000) 1.31
Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos (1990) 1.25
Modification of distinct aspects of photomorphogenesis via targeted expression of mammalian biliverdin reductase in transgenic Arabidopsis plants. Plant Physiol (1999) 1.23
Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet (1987) 1.20
Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos (1996) 1.18
Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens (1985) 1.18
Initial clinical experience with a new peripheral vasodilator, PR-G-138-Cl, in hypertensive patients. Eur J Clin Pharmacol (1975) 1.17
Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers. Antimicrob Agents Chemother (1992) 1.16
Identification of the biologically active form of sulindac. J Pharmacol Exp Ther (1977) 1.14
Determination of indinavir in human cerebrospinal fluid and plasma by solid-phase extraction and high-performance liquid chromatography with column switching. J Chromatogr B Biomed Sci Appl (1999) 1.14
Effect of enterohepatic circulation on the pharmacokinetics of diflunisal in rats. Drug Metab Dispos (1985) 1.12
Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metab Dispos (1980) 1.11
Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos (1992) 1.10
Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet (1982) 1.09
Herpes simplex virus gene products required for viral inhibition of expression of G1-phase functions. Virology (2001) 1.07
Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med (1993) 1.06
Inhibition of ferritin reduction by pyrazolo(3,4d)pyrimidines. Arch Biochem Biophys (1973) 1.06
Kinetic parameter estimation by numerical algorithms and multiple linear regression: theoretical. J Pharm Sci (1977) 1.05
Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab Dispos (1975) 1.05
In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos (1990) 1.03
Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm (1976) 1.03
Transdermal administration of clonidine for treatment of high BP. Arch Intern Med (1984) 1.03
A study of hypertension in the inner city. A student hypertension survey. Am Heart J (1973) 1.02
Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc (1986) 1.02
Comparative metabolism of aspartame in experimental animals and humans. J Toxicol Environ Health (1976) 1.02
Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos (1992) 1.01
Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol (1982) 0.99
Metabolism of a new hypolipidemic agent, 2-acetamidoethyl(p-chlorophenyl) (m-trifluoromethylphenoxy)-acetate (halofenate) in the rat, dog, rhesus monkey and man. J Pharmacol Exp Ther (1971) 0.99
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int (1998) 0.99
Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab Dispos (1988) 0.97
The effects of probenecid upon the individual components of indomethacin elimination. J Pharmacol Exp Ther (1977) 0.97
Essential hypertension. Br J Clin Pharmacol (1979) 0.96
The disposition of sulindac. Clin Pharmacol Ther (1977) 0.94
Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives. J Med Chem (1983) 0.92
Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens (1990) 0.91
Analgesic efficacy of low-dose ibuprofen in dental extraction pain. Pharmacotherapy (1987) 0.89
Urinary excretion kinetics of famotidine in rats. Drug Metab Dispos (1987) 0.88
Assay methodology for quantification of the ester and ether glucuronide conjugates of diflunisal in human urine. J Chromatogr (1985) 0.88
Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. Drug Metab Rev (1981) 0.86
The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther (1997) 0.86
Comparative effects of H2-receptor antagonists on drug interaction in rats. Drug Metab Dispos (1987) 0.86
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med (1993) 0.85
Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry. J Mass Spectrom (2001) 0.85
Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. J Cardiovasc Pharmacol (1987) 0.85
Potentiation of hypoglycemic effect of sulfonylureas by halofenate. N Engl J Med (1975) 0.85
Uricosurics and xanthine oxidase inhibitors: a single-dose assay. Curr Ther Res Clin Exp (1970) 0.85
Dose-dependent pharmacokinetics of diflunisal in rats: dual effects of protein binding and metabolism. J Pharmacol Exp Ther (1985) 0.84
Pharmacokinetics of Sulindac. Acta Rhumatol Belg (1980) 0.84
Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol (1995) 0.84
Purine metabolism in the chick embryo; effects of uricogenesis and xanthine oxidase inhibition. Mol Pharmacol (1968) 0.83
Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab Dispos (1990) 0.83
Enterohepatic circulation of sulindac and metabolites. Clin Pharmacol Ther (1983) 0.83
Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos (1994) 0.83
4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors. J Med Chem (1975) 0.83
Minoxidil treatment of severe hypertension. Curr Ther Res Clin Exp (1975) 0.83
Efficacy of an antihypertensive agent. Comparison of methyldopa and hydrochlorothiazide in combination and singly. JAMA (1975) 0.83
Comparative disposition of sulindac and metabolites in five species. Biochem Pharmacol (1978) 0.82
Bioavailability of dexamethasone. II. Dexamethasone phosphate. Clin Pharmacol Ther (1975) 0.82
Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes. Drug Metab Dispos (1981) 0.82
2-pyridylimidazoles as inhibitors of xanthine oxidase. J Med Chem (1977) 0.82
The influence of liver dysfunction on the pharmacokinetics of carprofen. J Clin Pharmacol (1985) 0.82
Determination of famotidine in human plasma by high performance liquid chromatography with column switching. J Pharm Biomed Anal (1998) 0.82
Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther (1996) 0.81
Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. J Pharmacokinet Biopharm (1978) 0.81
Kinetic studies on the competition between famotidine and cimetidine in rats. Evidence of multiple renal secretory systems for organic cations. Drug Metab Dispos (1988) 0.81
Efficacy and acceptability of different dosage schedules of clonidine. Clin Pharmacol Ther (1977) 0.81
Bioavailability assessment under quasi- and nonsteady-state conditions. I: theoretical considerations. J Pharm Sci (1975) 0.81
Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. Br J Clin Pharmacol (1987) 0.80
Lack of glutethimide effect of adrenal. J Clin Endocrinol Metab (1967) 0.80
A multicenter analgesic study using single doses of placebo, propoxyphene and acetaminophen. J Med (1977) 0.80
Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology (1989) 0.80
Letter: Gastric ulceration after "slow-K". N Engl J Med (1976) 0.80
Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol (1987) 0.80
Biliary secretion of sulindac and metabolites in man. Biopharm Drug Dispos (1984) 0.80
Novel oral medication delivery system for famotidine. J Clin Pharmacol (1995) 0.80
Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. Arch Intern Med (1989) 0.80